Are you Dr. Bartsch?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 6 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1441 Eastlake Ave
Ste 7416
Los Angeles, CA 90089Phone+1 323-865-3700Fax+1 323-865-0120
Clinical Trials
- Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. Start of enrollment: 2020 Feb 10
Publications & Presentations
PubMed
- 66 citationsHydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only SeriesGeorg Bartsch, Rainer Kuefer, Juergen E. Gschwend, Robert de Petriconi, Richard E. Hautmann
European Urology. 2007-03-01 - 28 citationsUse of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.Georg Bartsch, Anirban P. Mitra, Sheetal A. Mitra, Arpit A. Almal, Kenneth Steven
The Journal of Urology. 2016-02-01 - 63 citationsChemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (−)-Gossypol (AT-101)Jens Mani, Stefan Vallo, Stefanie Rakel, Patrick Antonietti, Florian Gessler
BMC Cancer. 2015-04-07
